KYMR

Kymera Therapeutics is developing KT-621, an oral STAT6 degrader in phase IIb trials for atopic dermatitis and eosinophilic asthma. The company completed enrollment in the BROADEN2 study ahead of schedule with top-line data expected by end of 2026.

Future growth depends on trial outcomes, regulatory approval, and successful commercialization. The company faces competition from Arvinas and Nurix in the protein degradation therapy space.